Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 16, 2025

Stock market today: Dow, S&P 500 slip, Nasdaq snaps three-day losing streak as Tesla climbs to record

View original at finance.yahoo.com
Stock market today: Dow, S&P 500 slip, Nasdaq snaps three-day losing streak as Tesla climbs to record US stocks diverged on Tuesday, Tesla (TSLA) stock hitting a new record at the same time that the Dow and S&P 500 slumped as investors saw a mixed picture from updates on the labor market…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Brent crude prices will slip into the $50s per barrel in 2026, potentially dropping into $40s or $30s if OPEC+ doesn't cut production

    80% confidence
  • The Amazon partnership renewal was largely in line with the current program and has been a win-win on both sides

    80% confidence
  • Bitcoin has been trading in a choppy range between 85k-94k with continued lack of interest and low volumes across crypto markets

    80% confidence
  • Brent crude prices will slip into the $50s per barrel in 2026, potentially dropping into $40s or $30s if production continues

    80% confidence
  • November jobs report data has a pretty big margin of error due to government shutdown and DOGE cuts, with revisions expected in January

    80% confidence
  • Pfizer faces challenges with no re-rating catalyst as company works through multi-year loss of exclusivity period until 2029

    80% confidence
  • Ukraine has secured a deal for US security guarantees in bid to end the war

    80% confidence
  • The Federal Reserve needs to be careful in assessing household survey data and look at it with a somewhat skeptical eye

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500 slip, Nasdaq snaps three-day losing streak as Tesla climbs to record — Source | Via News | ViaNews Market